StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure
This article was originally published in The Tan Sheet
The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.
You may also be interested in...
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.